Psychiatric disease

First large genetic study of bipolar disorder in Asian populations launches

aviveros@broadinstitute.org — Mon, 31 Oct 2022 16:53:52 +0000

Q&A: How to jump-start new psychiatric and neurological drug development

By Tom Ulrich December 18, 2023

Q&A: How to jump-start new psychiatric and neurological drug development

Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them

By Tom Ulrich

December 18, 2023

Steven Hyman

We asked Hyman, who is also a core institute member at ӳ��ý, to talk about the new framework and what he thinks are the biggest opportunities.

The following conversation was edited for length and clarity.

Why did you and your colleagues with the NASEM Forum decide to write this report?

So the need and the markets are there. The question becomes, under what circumstances would industry rebuild the infrastructure they need to re-engage in neuroscience and psychiatric development?

What do you think it will take for industry to re-engage in this space?

Your review article discussed the need to study genetically diverse patient samples. Can you expand on that?

There is both scientific benefit and a health equity imperative in looking across all of humanity. I see this as a moral necessity.

How important will new animal models be?

Where do industry and research institutes like the Stanley Center fit into your framework?

Do you think the roadmap you've laid out is something the players in the field will find realistic?

Paper cited

Tags:

ӳ��ý Discovery Center in Cambridge opens to the public this October

kzusi@broadinstitute.org — Mon, 19 Sep 2022 14:53:09 +0000

Q&A: How to jump-start new psychiatric and neurological drug development

By Tom Ulrich December 18, 2023

Q&A: How to jump-start new psychiatric and neurological drug development

Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them

By Tom Ulrich

December 18, 2023

Steven Hyman

We asked Hyman, who is also a core institute member at ӳ��ý, to talk about the new framework and what he thinks are the biggest opportunities.

The following conversation was edited for length and clarity.

Why did you and your colleagues with the NASEM Forum decide to write this report?

So the need and the markets are there. The question becomes, under what circumstances would industry rebuild the infrastructure they need to re-engage in neuroscience and psychiatric development?

What do you think it will take for industry to re-engage in this space?

Your review article discussed the need to study genetically diverse patient samples. Can you expand on that?

There is both scientific benefit and a health equity imperative in looking across all of humanity. I see this as a moral necessity.

How important will new animal models be?

Where do industry and research institutes like the Stanley Center fit into your framework?

Do you think the roadmap you've laid out is something the players in the field will find realistic?

Paper cited

Tags:

New study shows how microglia are prompted to change their state to adapt to different areas of the brain

kzusi@broadinstitute.org — Wed, 10 Aug 2022 21:47:28 +0000

Q&A: How to jump-start new psychiatric and neurological drug development

By Tom Ulrich December 18, 2023

Q&A: How to jump-start new psychiatric and neurological drug development

Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them

By Tom Ulrich

December 18, 2023

Steven Hyman

We asked Hyman, who is also a core institute member at ӳ��ý, to talk about the new framework and what he thinks are the biggest opportunities.

The following conversation was edited for length and clarity.

Why did you and your colleagues with the NASEM Forum decide to write this report?

So the need and the markets are there. The question becomes, under what circumstances would industry rebuild the infrastructure they need to re-engage in neuroscience and psychiatric development?

What do you think it will take for industry to re-engage in this space?

Your review article discussed the need to study genetically diverse patient samples. Can you expand on that?

There is both scientific benefit and a health equity imperative in looking across all of humanity. I see this as a moral necessity.

How important will new animal models be?

Where do industry and research institutes like the Stanley Center fit into your framework?

Do you think the roadmap you've laid out is something the players in the field will find realistic?

Paper cited

Tags:

Two large studies reveal genes and genome regions that influence schizophrenia risk

tulrich@broadinstitute.org — Wed, 06 Apr 2022 15:00:20 +0000

Q&A: How to jump-start new psychiatric and neurological drug development

By Tom Ulrich December 18, 2023

Q&A: How to jump-start new psychiatric and neurological drug development

Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them

By Tom Ulrich

December 18, 2023

Steven Hyman

We asked Hyman, who is also a core institute member at ӳ��ý, to talk about the new framework and what he thinks are the biggest opportunities.

The following conversation was edited for length and clarity.

Why did you and your colleagues with the NASEM Forum decide to write this report?

So the need and the markets are there. The question becomes, under what circumstances would industry rebuild the infrastructure they need to re-engage in neuroscience and psychiatric development?

What do you think it will take for industry to re-engage in this space?

Your review article discussed the need to study genetically diverse patient samples. Can you expand on that?

There is both scientific benefit and a health equity imperative in looking across all of humanity. I see this as a moral necessity.

How important will new animal models be?

Where do industry and research institutes like the Stanley Center fit into your framework?

Do you think the roadmap you've laid out is something the players in the field will find realistic?

Paper cited

Tags:

A path to promising treatments for schizophrenia

Corie Lok — Wed, 06 Apr 2022 15:00:03 +0000

Q&A: How to jump-start new psychiatric and neurological drug development

By Tom Ulrich December 18, 2023

Q&A: How to jump-start new psychiatric and neurological drug development

Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them

By Tom Ulrich

December 18, 2023

Steven Hyman

We asked Hyman, who is also a core institute member at ӳ��ý, to talk about the new framework and what he thinks are the biggest opportunities.

The following conversation was edited for length and clarity.

Why did you and your colleagues with the NASEM Forum decide to write this report?

So the need and the markets are there. The question becomes, under what circumstances would industry rebuild the infrastructure they need to re-engage in neuroscience and psychiatric development?

What do you think it will take for industry to re-engage in this space?

Your review article discussed the need to study genetically diverse patient samples. Can you expand on that?

There is both scientific benefit and a health equity imperative in looking across all of humanity. I see this as a moral necessity.

How important will new animal models be?

Where do industry and research institutes like the Stanley Center fit into your framework?

Do you think the roadmap you've laid out is something the players in the field will find realistic?

Paper cited

Tags:

Three autism risk genes have similar effects on brain development, but by different routes

tulrich@broadinstitute.org — Wed, 02 Feb 2022 16:32:08 +0000

Q&A: How to jump-start new psychiatric and neurological drug development

By Tom Ulrich December 18, 2023

Q&A: How to jump-start new psychiatric and neurological drug development

Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them

By Tom Ulrich

December 18, 2023

Steven Hyman

We asked Hyman, who is also a core institute member at ӳ��ý, to talk about the new framework and what he thinks are the biggest opportunities.

The following conversation was edited for length and clarity.

Why did you and your colleagues with the NASEM Forum decide to write this report?

So the need and the markets are there. The question becomes, under what circumstances would industry rebuild the infrastructure they need to re-engage in neuroscience and psychiatric development?

What do you think it will take for industry to re-engage in this space?

Your review article discussed the need to study genetically diverse patient samples. Can you expand on that?

There is both scientific benefit and a health equity imperative in looking across all of humanity. I see this as a moral necessity.

How important will new animal models be?

Where do industry and research institutes like the Stanley Center fit into your framework?

Do you think the roadmap you've laid out is something the players in the field will find realistic?

Paper cited

Tags:

Some brain disorders exhibit similar circuit malfunctions

Corie Lok — Wed, 30 Jun 2021 15:21:19 +0000

Q&A: How to jump-start new psychiatric and neurological drug development

By Tom Ulrich December 18, 2023

Q&A: How to jump-start new psychiatric and neurological drug development

Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them

By Tom Ulrich

December 18, 2023

Steven Hyman

We asked Hyman, who is also a core institute member at ӳ��ý, to talk about the new framework and what he thinks are the biggest opportunities.

The following conversation was edited for length and clarity.

Why did you and your colleagues with the NASEM Forum decide to write this report?

So the need and the markets are there. The question becomes, under what circumstances would industry rebuild the infrastructure they need to re-engage in neuroscience and psychiatric development?

What do you think it will take for industry to re-engage in this space?

Your review article discussed the need to study genetically diverse patient samples. Can you expand on that?

There is both scientific benefit and a health equity imperative in looking across all of humanity. I see this as a moral necessity.

How important will new animal models be?

Where do industry and research institutes like the Stanley Center fit into your framework?

Do you think the roadmap you've laid out is something the players in the field will find realistic?

Paper cited

Tags:

Autonomy, equity, and cultural considerations: Bioethicists discuss mental health genetics in Africa

tulrich@broadinstitute.org — Thu, 08 Oct 2020 04:00:00 +0000

Q&A: How to jump-start new psychiatric and neurological drug development

By Tom Ulrich December 18, 2023

Q&A: How to jump-start new psychiatric and neurological drug development

Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them

By Tom Ulrich

December 18, 2023

Steven Hyman

We asked Hyman, who is also a core institute member at ӳ��ý, to talk about the new framework and what he thinks are the biggest opportunities.

The following conversation was edited for length and clarity.

Why did you and your colleagues with the NASEM Forum decide to write this report?

So the need and the markets are there. The question becomes, under what circumstances would industry rebuild the infrastructure they need to re-engage in neuroscience and psychiatric development?

What do you think it will take for industry to re-engage in this space?

Your review article discussed the need to study genetically diverse patient samples. Can you expand on that?

There is both scientific benefit and a health equity imperative in looking across all of humanity. I see this as a moral necessity.

How important will new animal models be?

Where do industry and research institutes like the Stanley Center fit into your framework?

Do you think the roadmap you've laid out is something the players in the field will find realistic?

Paper cited

Tags:

Meet members of the next generation of psychiatric genetics researchers in Kenya and Uganda

Corie Lok — Thu, 08 Oct 2020 04:00:00 +0000

Q&A: How to jump-start new psychiatric and neurological drug development

By Tom Ulrich December 18, 2023

Q&A: How to jump-start new psychiatric and neurological drug development

Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them

By Tom Ulrich

December 18, 2023

Steven Hyman

We asked Hyman, who is also a core institute member at ӳ��ý, to talk about the new framework and what he thinks are the biggest opportunities.

The following conversation was edited for length and clarity.

Why did you and your colleagues with the NASEM Forum decide to write this report?

So the need and the markets are there. The question becomes, under what circumstances would industry rebuild the infrastructure they need to re-engage in neuroscience and psychiatric development?

What do you think it will take for industry to re-engage in this space?

Your review article discussed the need to study genetically diverse patient samples. Can you expand on that?

There is both scientific benefit and a health equity imperative in looking across all of humanity. I see this as a moral necessity.

How important will new animal models be?

Where do industry and research institutes like the Stanley Center fit into your framework?

Do you think the roadmap you've laid out is something the players in the field will find realistic?

Paper cited

Tags: